Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345
A phase Ia study to evaluate the safety, tolerance, pharmacokinetics and preliminary efficacy of IBI345 in patients with CLDN18.2 positive solid tumors
CLDN18.2 Positive Solid Tumors
DRUG: IBI345
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0., up to 2 years
Objective Response Rate (ORR) according to RECIST version 1.1, Defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR); a confirmed response is a response that persists on repeat-imaging ≥4 weeks after initial documentation of response., up to 2 years|Duration of Response (DOR) according to RECIST version 1.1, Defined as time from date of first objective response (either CR or PR) to first documentation of radiographic disease progression or death due to any cause, whichever occurs first., up to 2 years|Disease Control Rate (DCR) according to RECIST version 1.1, Defined as the proportion of subjects who have achieved CR, PR, or stable disease (duration of stable disease should be ≥3 months)., up to 2 years|Time to Response (TTR) according to RECIST version 1.1, Defined as the time from first dose to first documentation of objective response (either CR or PR)., up to 2 years|Progression-Free Survival (PFS) according to RECIST version 1.1, Defined as the time from first dose to first documentation of radiographic disease progression or death due to any cause, whichever occurs first., up to 2 years|Overall Survival (OS) according to RECIST version 1.1, Defined as the time from first dose to the date of death due to any cause., up to 2 years|Peak Plasma Concentration (Cmax), up to 1 years|Area under theplasma concentration versus time curve (AUC), up to 1 years|Time of maximum drug concentration in hours [Tmax], up to 1 years|Elimination half-life in hours [t1/2], up to 1 years|Clearance (CL), up to 1 years|Distribution Volume (Vd), up to 1 years|Number of Participants With anti-drug antibody (ADA), up to 1 years|Number of Participants With Neutralizing Antibodies (NAbs), up to 1 years
A phase Ia study to evaluate the safety, tolerance, pharmacokinetics and preliminary efficacy of IBI345 in patients with CLDN18.2 positive solid tumors